[Effect of a novel aminosteroid on animal model of murine myelomonocytic leukemia].
To evaluate the effect of a novel aminosteroid on murine myelomonocytic leukemia, BALB/c mice were treated by the novel aminosteroid for 7 days after receiving 1 x 10(6) WEHI-3B(myelomonocytic leukemia) cells intraperitoneally. The counts and classification of white blood cells obtained from tail blood were determined on the day before transplanting WEHI-3B cells and 7, 14, 21, 28 days after transplantation. Undifferentiated cell percentage of bone marrow and spleen weight were checked 30 days after transplantation. The results demonstrated that the above indexes of mice treated with the novel aminosteroid were decreased compared with those treated with normal saline(NS). Decrease of the indexes showed a dose-dependent relationship ranging from 5-20 mg.kg-1.d-1. It is suggested that leukemia mice could be effectively treated by the novel aminosteroid and the efficacy maybe paralleled with the dosage of the novel aminosteroid.
Na
X D
XD
Department of Physiology, Hunan Medical University, Changsha 410078.
He
Q
Q
Jiang
D Z
DZ
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D001854:Bone Marrow Cells / Q000473:pathology; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D003561:Cytarabine / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D015479:Leukemia, Myelomonocytic, Acute / Q000473:pathology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D011897:Random Allocation
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine